STARD4 and posterior cortical atrophy: By increasing enzalutamide efficacy through increased apoptosis, diminished proliferation, and reduced lipid droplet size, STARD4 overexpression has emerged as a promising strategy for improving outcomes in patients with advanced or treatment-resistant PCa.